{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:45:50Z","timestamp":1782215150706,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004196","name":"Odense Universitetshospital","doi-asserted-by":"publisher","award":["Centre for Personalized Response Monitoring in Oncology (PREMIO)"],"award-info":[{"award-number":["Centre for Personalized Response Monitoring in Oncology (PREMIO)"]}],"id":[{"id":"10.13039\/501100004196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013814","name":"Klinisk Institut, Syddansk Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013814","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Odense University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to determine the organ-specific accuracy of [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT in identifying immune-related adverse events (irAEs) in patients with high-risk (stage III\/IV) surgically resected melanoma treated with an adjuvant immune checkpoint inhibitor (ICI) and determine the incidence of irAEs within the first year after starting treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>This registry-based study included individuals who had undergone surgical removal of melanoma and were undergoing adjuvant ICI treatment (either nivolumab or pembrolizumab). The study specifically enrolled patients who had undergone both a baseline and at least one subsequent follow-up [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT scan. Follow-up scans were performed every third month in the first year after surgery to screen for disease recurrence. We retrospectively compared the follow-up scans with baseline scans to identify irAEs. Clinical information on irAEs was obtained from medical records and served as a reference standard for determining the accuracy of [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 123 patients with 363 [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT scans were included, and 65 patients (52.8%) developed irAEs. In decreasing order, the organ-specific incidences of irAEs were: skin 26\/65 (40%), muscle and joints 21\/65 (32.3%), intestines 13\/65 (20%), thyroid gland 12\/65 (18.5%), lungs 4\/65 (6.2%), and heart 2\/65 (3.1%). The sensitivities and specificities of [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT for diagnosing irAEs were: skin 19% (95% CI: 7\u201339%) and 95% (88\u201398%), muscles and joints 71% (48\u201389%) and 83% (75\u201390%), intestines 100% (75\u2013100%) and 85% (77\u201391%); thyroid gland 92% (62\u201399%) and 95% (89\u201398%), lungs 75% (19\u201399%) and 90% (83\u201395%), and heart 50% (13\u201399%) and 97% (92\u201399%), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]FDG-PET\/CT generally had moderate to high sensitivities (except for skin and heart) and specificities in diagnosing irAEs in patients receiving adjuvant ICI; this could be suggested to be systematically assessed and reported in scan reports.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11604-024-01554-y","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T03:01:29Z","timestamp":1710903689000},"page":"753-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Organ-specific accuracy of [18F]FDG-PET\/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor"],"prefix":"10.1007","volume":"42","author":[{"given":"Birte Molvik","family":"Gideonse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Birkeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Holm","family":"Vilstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Grupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6761-8126","authenticated-orcid":false,"given":"Mohammad","family":"Naghavi-Behzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oke","family":"Gerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene Grubbe","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"1554_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.suc.2019.09.009","volume":"100","author":"AA Onitilo","year":"2020","unstructured":"Onitilo AA, Wittig JA. Principles of immunotherapy in melanoma. Surg Clin North Am. 2020;100:161\u201373.","journal-title":"Surg Clin North Am"},{"key":"1554_CR2","first-page":"572","volume":"7","author":"A Sandru","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572\u20136.","journal-title":"J Med Life"},{"key":"1554_CR3","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"1554_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"1554_CR5","first-page":"704","volume":"11","author":"N Sabag","year":"2020","unstructured":"Sabag N, Yakobson A, Silberstein E. Recent changes and innovations in melanoma treatment: a review. Isr Med Assoc J. 2020;11:704\u201310.","journal-title":"Isr Med Assoc J"},{"key":"1554_CR6","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","volume":"31","author":"O Michielin","year":"2020","unstructured":"Michielin O, Van Akkooi A, Lorigan P, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1449\u201361.","journal-title":"Ann Oncol"},{"key":"1554_CR7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","volume":"6","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Kicinski M, Blank CU, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo. JAMA Oncol. 2020;6:519.","journal-title":"JAMA Oncol"},{"key":"1554_CR8","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789\u2013801.","journal-title":"N Engl J Med"},{"key":"1554_CR9","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691\u20137.","journal-title":"J Clin Oncol"},{"key":"1554_CR10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s41747-020-00190-1","volume":"4","author":"M Unterrainer","year":"2020","unstructured":"Unterrainer M, Ruzicka M, Fabritius MP, et al. PET\/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020;4:63.","journal-title":"Eur Radiol Exp"},{"key":"1554_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cei.13421","volume":"200","author":"P Urwyler","year":"2020","unstructured":"Urwyler P, Earnshaw I, Bermudez M, et al. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol. 2020;200:141\u201354.","journal-title":"Clin Exp Immunol"},{"key":"1554_CR12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5114\/wo.2018.73889","volume":"2018","author":"I Lugowska","year":"2018","unstructured":"Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Wsp\u00f3\u0142czesna Onkologia. 2018;2018:61\u20137.","journal-title":"Wsp\u00f3\u0142czesna Onkologia"},{"key":"1554_CR13","doi-asserted-by":"crossref","unstructured":"Ellithi M, Elnair R, Chang GV, Abdallah MA. Toxicities of immune checkpoint inhibitors: itis-ending adverse reactions and more. Cureus 2020.","DOI":"10.7759\/cureus.6935"},{"key":"1554_CR14","volume":"9","author":"M Mandala","year":"2021","unstructured":"Mandala M, Larkin J, Ascierto PA, et al. Adjuvant nivolumab for stage III\/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. J Immunother Cancer. 2021;9: e003188.","journal-title":"J Immunother Cancer"},{"key":"1554_CR15","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874471013666191223153755","volume":"13","author":"M Farsad","year":"2020","unstructured":"Farsad M. FDG PET\/CT in the staging of lung cancer. Curr Radiopharm. 2020;13:195\u2013203.","journal-title":"Curr Radiopharm"},{"key":"1554_CR16","first-page":"255","volume":"7","author":"PH Vensby","year":"2017","unstructured":"Vensby PH, Schmidt G, Kj\u00e6r A, Fischer BM. The value of FDG PET\/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging. 2017;7:255\u201362.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1554_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11307-020-01526-4","volume":"23","author":"R Nakamoto","year":"2021","unstructured":"Nakamoto R, Zaba LC, Rosenberg J, et al. Imaging characteristics and diagnostic performance of 2-deoxy-2-[(18)F]fluoro-D-Glucose PET\/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy. Mol Imaging Biol. 2021;23:139\u201347.","journal-title":"Mol Imaging Biol"},{"key":"1554_CR18","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s00259-022-05704-0","volume":"49","author":"JAS Andersen","year":"2022","unstructured":"Andersen JAS, Spatzek AD, Vilstrup MH, et al. The diagnostic accuracy and clinical impact of FDG-PET\/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. Eur J Nucl Med Mol Imaging. 2022;49:2342\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR19","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.2967\/jnumed.117.197988","volume":"58","author":"H Jadvar","year":"2017","unstructured":"Jadvar H, Colletti PM, Delgado-Bolton R, et al. Appropriate use criteria for 18F-FDG PET\/CT in restaging and treatment response assessment of malignant disease. J Nucl Med. 2017;58:2026\u201337.","journal-title":"J Nucl Med"},{"key":"1554_CR20","unstructured":"Sundhedsstyrelsen. Pakkeforl\u00f8b for moderm\u00e6rkekr\u00e6ft i huden. 2020, July; 34."},{"key":"1554_CR21","unstructured":"Danish melanoma database. Available from https:\/\/www.danishhealthdata.com\/find-health-data\/Dansk-Melanom-Database."},{"key":"1554_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"key":"1554_CR23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"1554_CR24","unstructured":"Guideline for Assessment and Treatment of IrAEs. 2018. Avalible from https:\/\/dsko.org\/wp-content\/uploads\/2018\/09\/CheckPointInhib-Tox-2018-10-juli.pdf."},{"key":"1554_CR25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR26","first-page":"211","volume":"38","author":"E Lopci","year":"2023","unstructured":"Lopci E, Castello A, Filippi L. Novelties from the Joint EANM\/SNMMI\/ANZSNM Guidelines on Immunotherapy. Cancer Biother Radiopharm. 2023;38:211\u20135.","journal-title":"Cancer Biother Radiopharm"},{"key":"1554_CR27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40644-022-00512-z","volume":"22","author":"E Lopci","year":"2022","unstructured":"Lopci E, Aide N, Dimitrakopoulou-Strauss A, et al. Perspectives on joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards for [(18)F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors. Cancer Imaging. 2022;22:73.","journal-title":"Cancer Imaging"},{"key":"1554_CR28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/1754-9485.13390","volume":"66","author":"MH Cherk","year":"2022","unstructured":"Cherk MH, Nadebaum DP, Barber TW, et al. (18) F-FDG PET\/CT features of immune-related adverse events and pitfalls following immunotherapy. J Med Imaging Radiat Oncol. 2022;66:483\u201394.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1554_CR29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s12094-022-02840-9","volume":"24","author":"G Tatar","year":"2022","unstructured":"Tatar G, Al\u00e7in G, Sengul Samanci N, et al. Diagnostic impact of (18)F-FDG PET\/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy. Clin Transl Oncol. 2022;24:1903\u201313.","journal-title":"Clin Transl Oncol"},{"key":"1554_CR30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45:376\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR31","doi-asserted-by":"crossref","first-page":"20190832","DOI":"10.1259\/bjr.20190832","volume":"93","author":"N Gandy","year":"2020","unstructured":"Gandy N, Arshad MA, Wallitt KL, et al. Immunotherapy-related adverse effects on (18)F-FDG PET\/CT imaging. Br J Radiol. 2020;93:20190832.","journal-title":"Br J Radiol"},{"key":"1554_CR32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/imt-2018-0146","volume":"11","author":"N Lang","year":"2019","unstructured":"Lang N, Dick J, Slynko A, et al. Clinical significance of signs of autoimmune colitis in (18)F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. Immunotherapy. 2019;11:667\u201376.","journal-title":"Immunotherapy"},{"key":"1554_CR33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12149-010-0439-x","volume":"25","author":"A Toriihara","year":"2011","unstructured":"Toriihara A, Yoshida K, Umehara I, Shibuya H. Normal variants of bowel FDG uptake in dual-time-point PET\/CT imaging. Ann Nucl Med. 2011;25:173\u20138.","journal-title":"Ann Nucl Med"},{"key":"1554_CR34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5946\/ce.2012.45.2.109","volume":"45","author":"BI Jang","year":"2012","unstructured":"Jang BI. Benign Colonic18F-FDG uptake on whole-body FDG-PET scan. Clin Endosc. 2012;45:109.","journal-title":"Clin Endosc"},{"key":"1554_CR35","first-page":"271","volume":"11","author":"D Gelston","year":"2021","unstructured":"Gelston D, Brosler SC, Vazquez J, et al. Utility of FDG PET\/CT in assessing bowel inflammation. Am J Nucl Med Mol Imaging. 2021;11:271\u20139.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"1554_CR36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00259-007-0563-6","volume":"35","author":"E Gontier","year":"2008","unstructured":"Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008;35:95\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00259-009-1330-7","volume":"37","author":"T \u00d6z\u00fclker","year":"2010","unstructured":"\u00d6z\u00fclker T, \u00d6z\u00fclker F, Mert M, \u00d6zpa\u00e7ac\u0131 T. Clearance of the high intestinal 18F-FDG uptake associated with metformin after stopping the drug. Eur J Nucl Med Mol Imaging. 2010;37:1011\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/RLU.0b013e318217399e","volume":"36","author":"B Bybel","year":"2011","unstructured":"Bybel B, Greenberg ID, Paterson J, et al. Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case-control analysis. Clin Nucl Med. 2011;36:452\u20136.","journal-title":"Clin Nucl Med"},{"key":"1554_CR39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.crad.2014.12.020","volume":"70","author":"K Agrawal","year":"2015","unstructured":"Agrawal K, Weaver J, Ngu R, Krishnamurthy MH. Clinical significance of patterns of incidental thyroid uptake at (18)F-FDG PET\/CT. Clin Radiol. 2015;70:536\u201343.","journal-title":"Clin Radiol"},{"key":"1554_CR40","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"Delivanis DA, Gustafson MP, Bornschlegl S, et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab. 2017;102:2770\u201380.","journal-title":"J Clin Endocrinol Metab"},{"key":"1554_CR41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00262-020-02712-7","volume":"70","author":"A Frelau","year":"2021","unstructured":"Frelau A, Palard-Novello X, Jali E, et al. Increased thyroid uptake on 18F-FDG PET\/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunol Immunother. 2021;70:679\u201387.","journal-title":"Cancer Immunol Immunother"},{"key":"1554_CR42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109168","volume":"117","author":"WT Rahman","year":"2019","unstructured":"Rahman WT, Wale DJ, Viglianti BL, et al. The impact of infection and inflammation in oncologic 18F-FDG PET\/CT imaging. Biomed Pharmacother. 2019;117: 109168.","journal-title":"Biomed Pharmacother"},{"key":"1554_CR43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1574886313666180508122332","volume":"13","author":"D Benfaremo","year":"2018","unstructured":"Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. Curr Drug Saf. 2018;13:150\u201364.","journal-title":"Curr Drug Saf"},{"key":"1554_CR44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","volume":"67","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya K, Benesova K, Schulz C, et al. Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunol Immunother. 2018;67:175\u201382.","journal-title":"Cancer Immunol Immunother"},{"key":"1554_CR45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","volume":"44","author":"ANM Wong","year":"2017","unstructured":"Wong ANM, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44:67\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR46","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","volume":"48","author":"N Ayati","year":"2021","unstructured":"Ayati N, Sadeghi R, Kiamanesh Z, et al. The value of 18F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:428\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR47","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","volume":"131","author":"E Chorti","year":"2020","unstructured":"Chorti E, Kanaki T, Zimmer L, et al. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis. Eur J Cancer. 2020;131:18\u201326.","journal-title":"Eur J Cancer"},{"key":"1554_CR48","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.chest.2018.03.056","volume":"154","author":"A Chopra","year":"2018","unstructured":"Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest. 2018;154:664\u201377.","journal-title":"Chest"},{"key":"1554_CR49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.iotech.2020.03.001","volume":"5","author":"EA Lim","year":"2020","unstructured":"Lim EA, Drake CG, Mintz A. Molecular imaging for cancer immunotherapy. Immunooncol Technol. 2020;5:10\u201321.","journal-title":"Immunooncol Technol"},{"key":"1554_CR50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cpet.2019.08.005","volume":"15","author":"RV Parghane","year":"2020","unstructured":"Parghane RV, Basu S. PET\/computed tomography in treatment response assessment in cancer: an overview with emphasis on the evolving role in response evaluation to immunotherapy and radiation therapy. PET Clin. 2020;15:101\u201323.","journal-title":"PET Clin"},{"key":"1554_CR51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1148\/rg.2021200093","volume":"41","author":"LB Costa","year":"2021","unstructured":"Costa LB, Queiroz MA, Barbosa FG, et al. Reassessing patterns of response to immunotherapy with PET: from morphology to metabolism. Radiographics. 2021;41:120\u201343.","journal-title":"Radiographics"},{"key":"1554_CR52","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1007\/s00259-020-04967-9","volume":"48","author":"N Ayati","year":"2021","unstructured":"Ayati N, Sadeghi R, Kiamanesh Z, et al. The value of (18)F-FDG PET\/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:428\u201348.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1554_CR53","doi-asserted-by":"crossref","unstructured":"Zhou X, Yao Z, Yang H et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 2020; 18.","DOI":"10.1186\/s12916-020-01549-2"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-024-01554-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01554-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T21:22:34Z","timestamp":1719868954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-024-01554-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1554"],"URL":"https:\/\/doi.org\/10.1007\/s11604-024-01554-y","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Region of Southern Denmark.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}